ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,321.41
0.25%
Dow Jones
39,872.99
0.17%
US Dollar vs MXN
16.6107
-0.07%
Brent Oil
82.055
-0.47%
Bitcoin
69,817.62
-0.45%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. AMEX
  6. Oragenics Inc (OGEN)

  7. Oragenics Inc (OGEN) Noticias

OGEN

Oragenics (OGEN)

Oragenics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:AMEX:OGEN
FechaHoraFuenteTítuloSímboloCompañía
17/05/202407:00Edgar (US Regulatory)Form 8-K - Current reportAMEX:OGENOragenics Inc
17/05/202407:00GlobeNewswire Inc.Oragenics, Inc. to Host Webinar Panel on Neurotrauma MedicineAMEX:OGENOragenics Inc
16/05/202407:00GlobeNewswire Inc.Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion TrialAMEX:OGENOragenics Inc
15/05/202412:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:OGENOragenics Inc
07/05/202407:00GlobeNewswire Inc.Oragenics Partners with Avance Clinical for Phase II Concussion Trial in AustraliaAMEX:OGENOragenics Inc
19/04/202416:50Business WireOragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing StandardsAMEX:OGENOragenics Inc
01/04/202408:05Business WireOragenics, Inc. Files 10K and Provides Company UpdateAMEX:OGENOragenics Inc
18/03/202406:00Business WireOragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating ConcussionAMEX:OGENOragenics Inc
06/03/202415:24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsAMEX:OGENOragenics Inc
05/03/202406:45Business WireOragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat ConcussionAMEX:OGENOragenics Inc
01/03/202415:04Business WireOragenics Announces Closing of Public OfferingAMEX:OGENOragenics Inc
29/02/202415:41Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:OGENOragenics Inc
27/02/202420:25Business WireOragenics Announces Pricing of Public OfferingAMEX:OGENOragenics Inc
27/02/202416:09Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesAMEX:OGENOragenics Inc
27/02/202415:33Business WireOragenics Announces Proposed Public OfferingAMEX:OGENOragenics Inc
12/02/202419:06Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipAMEX:OGENOragenics Inc
12/02/202415:41Business WireOragenics, Inc. Announces Leadership TransitionAMEX:OGENOragenics Inc
07/02/202407:00Business WireOragenics, Inc. Announces Expiration of Its Investment Banking Engagement AgreementAMEX:OGENOragenics Inc
05/02/202407:00Business WireOragenics, Inc. Preparing for Phase II Clinical Trials to Treat ConcussionAMEX:OGENOragenics Inc
23/01/202416:34Business WireOragenics Announces Termination of At-The-Market Offering ProgramAMEX:OGENOragenics Inc
22/01/202416:30Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesAMEX:OGENOragenics Inc
10/01/202415:37Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansAMEX:OGENOragenics Inc
02/01/202416:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:OGENOragenics Inc
02/01/202415:40Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:OGENOragenics Inc
02/01/202406:30Business WireOragenics Completes Acquisition of Odyssey Health’s Neurological AssetsAMEX:OGENOragenics Inc
30/11/202316:50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesAMEX:OGENOragenics Inc
16/11/202313:37Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialAMEX:OGENOragenics Inc
02/11/202306:00Business WireOragenics Issues Update to ShareholdersAMEX:OGENOragenics Inc
30/10/202315:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:OGENOragenics Inc
18/10/202307:30Business WireOragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of DirectorsAMEX:OGENOragenics Inc
 Showing the most relevant articles for your search:AMEX:OGEN

Su Consulta Reciente

NYSE
MRK
Merck
NASDAQ
AMZN
Amazon.com
USOTC
DTEGY
Deutsche Telekom (QX)
CCOM
SILVER
SILVER
USOTC
ADDYY
Adidas (QX)
COIN
ETHUSD
Ethereum
NASDAQ
AAPL
Apple
USOTC
BNPQY
BNP Paribas (QX)
USOTC
RHHBY
Roche (QX)
NYSE
JPM
JP Morgan Chase
NYSE
NKE
Nike
NASDAQ
TSLA
Tesla
CCOM
OILBRENT
Brent Oil
FX
EURUSD
Euro vs US Dollar
AMEX
XLE
Energy Select Sector SPDR
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados